SCHEMBL5756970

SCHEMBL5756970

Cc1ccc(-c2cnc(Cc3ccc(Cl)c(Cl)c3)[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SSTR3 P32745 1/20 0.42
NPY5R Q15761 4/20 0.42
HPGDS O60760 2/20 0.42
SCN5A Q14524 2/20 0.41
SCN10A Q9Y5Y9 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
ADORA2A P29274 3/20 0.41
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PDE10A Q9Y233 1/20 0.39
RNASEH1 O60930 1/20 0.39
ADORA1 P30542 1/20 0.39
SMPD3 Q9NY59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755506 0.88 PDE10A (0.41) SSTR3NPY5RHPGDSSCN5ASCN10A
SCHEMBL5759555 0.88 HPGDS (0.53) NPY5RHPGDSSLC6A2SLC6A4SLC6A3
SCHEMBL5758953 0.87 HPGDS (0.56) NPY5RHPGDSADORA2ASLC6A2SLC6A4
SCHEMBL5757949 0.87 ADORA2A (0.48) SSTR3HPGDSSCN10AADORA2AADORA1
SCHEMBL5759979 0.82 NPY5R (0.51) NPY5RHPGDSADORA2AADORA1
SCHEMBL5758452 0.80 HPGDS (0.57) NPY5RHPGDSPDE10A
SCHEMBL5759386 0.78 SCN10A (0.45) SSTR3HPGDSSCN5ASCN10ALMNA
SCHEMBL5758643 0.78 HPGDS (0.62) SSTR3NPY5RHPGDSPDE10A
SCHEMBL5758338 0.77 ADORA2A (0.43) HPGDSSCN5ASCN10AALDH1A1LMNA
SCHEMBL5757421 0.76 NPC1 (0.47) ALDH1A1LMNAHPGDALOX12ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP claimed
US-20030149089-A1 Antibacterial compounds SMITHKLINE BEECHAM CORPORATION 2003-08-07 US claimed
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP disclosed
US-6673941-B2 Disubstituted imidazoles useful in the treatment of bacterial infections AFFINIUM PHARMACEUTICALS, INC. (CA) 2004-01-06 US disclosed
US-6559172-B1 Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics SMITHKLINE BEECHAM CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149089-A1 Antibacterial compounds MRPL21, MRPS28, SPOUT1 SSTR3 2826/4885NPY5R 4061/4885HPGDS 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.